MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells
- 14 April 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (8), 1657-1667
- https://doi.org/10.1158/0008-5472.can-14-2061
Abstract
EGFR is upregulated in the majority of head and neck squamous cell carcinomas (HNSCC). However, many patients with HNSCC respond poorly to the EGFR inhibitors (EGFRI) cetuximab and erlotinib, despite tumor expression of EGFR. Gene expression analysis of erlotinib-treated HNSCC cells revealed an upregulation of genes involved in MyD88-dependent signaling compared with their respective vehicle-treated cell lines. We therefore investigated whether MyD88-dependent signaling may reduce the antitumor efficacy of EGFRIs in HNSCC. Erlotinib significantly upregulated IL6 secretion in HNSCC cell lines, which our laboratory previously reported to result in reduced drug efficacy. Suppression of MyD88 expression blocked erlotinib-induced IL6 secretion in vitro and increased the antitumor activity of erlotinib in vivo. There was little evidence of Toll-like receptor or IL18 receptor involvement in erlotinib-induced IL6 secretion. However, suppression of IL1R signaling significantly reduced erlotinib-induced IL6 production. A time-dependent increase of IL1α but not IL1β was observed in response to erlotinib treatment, and IL1α blockade significantly increased the antitumor activity of erlotinib and cetuximab in vivo. A pan-caspase inhibitor reduced erlotinib-induced IL1α secretion, suggesting that IL1α was released because of cell death. Human HNSCC tumors showed higher IL1α mRNA levels compared with matched normal tissue, and IL1α was found to be negatively correlated with survival in patients with HNSCC. Overall, the IL1α/IL1R/MYD88/IL6 pathway may be responsible for the reduced antitumor efficacy of erlotinib and other EGFRIs, and blockade of IL1 signaling may improve the efficacy of EGFRIs in the treatment of HNSCC. Cancer Res; 75(8); 1657–67. ©2015 AACR.Keywords
Other Versions
This publication has 34 references indexed in Scilit:
- Identification of microRNAs That Regulate TLR2-Mediated Trophoblast Apoptosis and Inhibition of IL-6 mRNAPLOS ONE, 2013
- The Interleukin-1α Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of CytokinesFrontiers in Immunology, 2013
- Erlotinib-Mediated Inhibition of EGFR Signaling Induces Metabolic Oxidative Stress through NOX4Cancer Research, 2011
- MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligandsProceedings of the National Academy of Sciences of the United States of America, 2010
- TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancerProceedings of the National Academy of Sciences of the United States of America, 2010
- Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung CancerClinical Cancer Research, 2010
- Pyroptosis: host cell death and inflammationNature Reviews Microbiology, 2009
- Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomasBritish Journal of Cancer, 2008
- EGFR inhibition as a therapy for head and neck squamous cell carcinomaExpert Opinion on Investigational Drugs, 2008
- Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinomaBMC Cancer, 2008